 |
Evolving Treatment Strategies in Major Mental Illnesses: A Focus on Schizophrenia and Bipolar Disorder CME/CE Author Information and Disclosures Release Date: February 19, 2008; Valid for credit through February 19, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 nursing contact hours (1.0 contact hours are in the area of pharmacology);
Pharmacists - 1.0 ACPE continuing education credits for pharmacists (0.1 CEUs) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Review the impact of schizophrenia and bipolar disorder on clinical well-being, functionality, and overall quality of life
- Highlight the safety and tolerability of atypical antipsychotics in schizophrenia and bipolar disorder management with a
focus on metabolic indices and extrapyramidal symptoms (EPS)
- Explore how best to implement emerging treatment data into schizophrenia and bipolar disorder management in order to achieve optimal clinical outcomes
Authors and Disclosures Michael E. Thase, MD
Disclosure: Michael E. Thase, MD, has disclosed that he has served as
an advisor or consultant to AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, MedAvante, Neuronetics, Novartis, Organon, Sepracor, Shire US, Supernus, and Wyeth. Dr. Thase has also disclosed that he has served on the speaker's bureau for AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth Pharmaceuticals, and has given expert testimony for Jones Day (Wyeth
Litigation) and Phillips Lytle (GlaxoSmithKline Litigation). Dr. Thase has also disclosed that he has equity holdings in MedAvante, and has received royalty or other income from American Psychiatric Publishing, Guilford Publications, and Herald House. Dr. Thase has also disclosed that his spouse is employed as the Senior Medical Director at Advogent (Formerly Cardinal Health). Michael T. Compton, MD, MPH
Disclosure:
Michael T. Compton, MD, MPH, has disclosed no relevant financial relationships. Bret Stetka, MD
Disclosure: Bret Stetka, MD, has disclosed no relevant financial relationships. Elizabeth Saenger, PhD
Disclosure: Elizabeth Saenger, PhD, has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
 Medscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Medscape is accredited by the American Council on Pharmacy Education as a provider of continuing pharmacy education. Medscape designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the American Council on Pharmacy Education (Universal Program Number 461-000-08-008-H01-P).
Contact This Provider
|
|
